Advanced Life Sciences

A New Solution to Quit Smoking

31M

Smokers in the US

11M

E-Cigs in the US

Nicotine Addiction Is Not a Problem of the Past

Smoking is still a global public health threat and despite having medication for decades, we’ve yet to eradicate this global epidemic.

1/3

of cancer deaths in the U.S. are attributed to cigarette smoking

8M

U.S. Deaths Nationwide

16M

Americans Live with Smoking- Related Disease

Let’s face it. Current treatments are failing. We’re here to change that.

While the majority of smokers in the US say they would like to quit and more than half make an attempt, only a tiny percentage of quit attempts are successful. No new smoking cessation treatments have been FDA approved in over fifteen years. With only two non-nicotine FDA-approved smoking cessation treatments, there are still no approved treatments specifically for e-cigarette smoking cessation.

Introducing

Cytisinicline

Derived from natural sources, including the seeds of the laburnum tree, cytisinicline is a potential new treatment for smoking cessation and nicotine addiction.

Helping smokers quit… with minimal side effects

In a recent trial, cytisinicline has been shown to effectively help even highly dependent smokers stop smoking. Cytisinicline binds to the same receptors as nicotine to reduce both withdrawal symptoms and satisfaction associated with smoking. And since it doesn’t bind as strongly to certain receptors, it is believed to have less potential to cause side effects—including nausea and vomiting.

90%

Trial participants had over 90% compliance with cytisinicline treatment

About Achieve

Achieve is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction.

Latest

 

Achieve Life Sciences Announces Participation at H.C. Wainwright 1st Annual Mental Health Conference

SEATTLE and VANCOUVER, British Columbia, June 21, 2022 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (NASDAQ: ACH

Read More

Achieve Life Sciences Awarded Grant from the National Institutes of Health to Conduct Phase 2 Trial of Cytisinicline in Nicotine e-cigarette Users

Company awarded $2.5 million to enable initiation of the Phase 2 ORCA-V1 clinical trial SEATTLE and VANCOUVER, British C

Read More

Achieve Life Sciences Announces Participation at LD Micro Invitational Conference

SEATTLE, Wash. and VANCOUVER, British Columbia, May 26, 2022 — Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-

Read More

Achieve Life Sciences Announces Participation at Best Ideas Virtual Investor Conference

SEATTLE, Wash. And VANCOUVER, British Columbia, May 13, 2022 — Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-

Read More

We can’t help but

Believe

And we’re looking for others like us who believe we can bring an end to this fight.
Will you join us?

  • Achieve Life Sciences US Headquarters
  • 22722 29th Dr SE, Suite 100
  • Bothell, WA 98021
  • Phone: (425) 686-1500
  • Vancouver – Principal Executive Office
  • 1040 W Georgia Street, Suite 1030
  • Vancouver, BC V6E 4H1